Lantern Pharma (LTRN) Research & Development (2020 - 2026)

Lantern Pharma (LTRN) has reported Research & Development for 7 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 41.64% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2026 stood at $8.7 million (down 39.26% YoY), and the FY2025 full-year result was $11.5 million, down 28.6% from the prior year.
• Research & Development rose to $1.8 million in Q2 2026 per LTRN's latest filing, from $1.7 million in the prior quarter.
• Across five years, Research & Development topped out at $4.3 million in Q4 2024 and bottomed at $702296.0 in Q3 2022.
• Historically, Research & Development has averaged $2.9 million across 5 years, with a median of $2.9 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Research & Development slumped 76.31% in 2022, then jumped 214.67% in 2023.
• Over 5 years, Research & Development stood at $2.3 million in 2022, then surged by 58.7% to $3.6 million in 2023, then advanced by 19.49% to $4.3 million in 2024, then slumped by 35.71% to $2.7 million in 2025, then tumbled by 34.75% to $1.8 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.8 million, $1.7 million, and $2.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.